Multiple Myeloma and SARS-CoV-2 Infection: Clinical Characteristics and Prognostic Factors of Inpatient Mortality

{ 'indexed': {'date-parts': [[2024, 3, 20]], 'date-time': '2024-03-20T00:36:53Z', 'timestamp': 1710895013667}, 'reference-count': 28, 'publisher': 'Springer Science and Business Media LLC', 'issue': '10', 'license': [ { 'start': { 'date-parts': [[2020, 10, 19]], 'date-time': '2020-10-19T00:00:00Z', 'timestamp': 1603065600000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by/4.0'}, { 'start': { 'date-parts': [[2020, 10, 19]], 'date-time': '2020-10-19T00:00:00Z', 'timestamp': 1603065600000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by/4.0'}], 'content-domain': {'domain': ['link.springer.com'], 'crossmark-restriction': False}, 'abstract': '<jats:title>Abstract</jats:title><jats:p>There is limited information on the characteristics, ' 'prognostic factors, and outcomes of patients with multiple myeloma (MM) hospitalized with ' 'COVID-19. This retrospective case series investigated 167 patients reported from 73 hospitals ' 'within the Spanish Myeloma Collaborative Group network in March and April, 2020. Outcomes ' 'were compared with 167 randomly selected, contemporary, age-/sex-matched noncancer patients ' 'with COVID-19 admitted at six participating hospitals. Among MM and noncancer patients, ' 'median age was 71 years, and 57% of patients were male; 75 and 77% of patients, respectively, ' 'had at least one comorbidity. COVID-19 clinical severity was moderate–severe in 77 and 89% of ' 'patients and critical in 8 and 4%, respectively. Supplemental oxygen was required by 47 and ' '55% of MM and noncancer patients, respectively, and 21%/9% vs 8%/6% required ' 'noninvasive/invasive ventilation. Inpatient mortality was 34 and 23% in MM and noncancer ' 'patients, respectively. Among MM patients, inpatient mortality was 41% in males, 42% in ' 'patients aged &gt;65 years, 49% in patients with active/progressive MM at hospitalization, ' 'and 59% in patients with comorbid renal disease at hospitalization, which were independent ' 'prognostic factors on adjusted multivariate analysis. This case series demonstrates the ' 'increased risk and identifies predictors of inpatient mortality among MM patients ' 'hospitalized with COVID-19.</jats:p>', 'DOI': '10.1038/s41408-020-00372-5', 'type': 'journal-article', 'created': { 'date-parts': [[2020, 10, 19]], 'date-time': '2020-10-19T14:07:20Z', 'timestamp': 1603116440000}, 'update-policy': 'http://dx.doi.org/10.1007/springer_crossmark_policy', 'source': 'Crossref', 'is-referenced-by-count': 53, 'title': 'Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of ' 'inpatient mortality', 'prefix': '10.1038', 'volume': '10', 'author': [ { 'ORCID': 'http://orcid.org/0000-0001-7908-0063', 'authenticated-orcid': False, 'given': 'Joaquín', 'family': 'Martínez-López', 'sequence': 'first', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0003-2390-1218', 'authenticated-orcid': False, 'given': 'María-Victoria', 'family': 'Mateos', 'sequence': 'additional', 'affiliation': []}, {'given': 'Cristina', 'family': 'Encinas', 'sequence': 'additional', 'affiliation': []}, {'given': 'Anna', 'family': 'Sureda', 'sequence': 'additional', 'affiliation': []}, { 'given': 'José Ángel', 'family': 'Hernández-Rivas', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ana', 'family': 'Lopez de la Guía', 'sequence': 'additional', 'affiliation': []}, {'given': 'Diego', 'family': 'Conde', 'sequence': 'additional', 'affiliation': []}, {'given': 'Isabel', 'family': 'Krsnik', 'sequence': 'additional', 'affiliation': []}, {'given': 'Elena', 'family': 'Prieto', 'sequence': 'additional', 'affiliation': []}, {'given': 'Rosalía', 'family': 'Riaza Grau', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-8106-8909', 'authenticated-orcid': False, 'given': 'Mercedes', 'family': 'Gironella', 'sequence': 'additional', 'affiliation': []}, {'given': 'María Jesús', 'family': 'Blanchard', 'sequence': 'additional', 'affiliation': []}, {'given': 'Nerea', 'family': 'Caminos', 'sequence': 'additional', 'affiliation': []}, { 'given': 'Carlos', 'family': 'Fernández de Larrea', 'sequence': 'additional', 'affiliation': []}, {'given': 'María Alicia', 'family': 'Senin', 'sequence': 'additional', 'affiliation': []}, {'given': 'Fernando', 'family': 'Escalante', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0003-2563-7510', 'authenticated-orcid': False, 'given': 'José Enrique', 'family': 'de la Puerta', 'sequence': 'additional', 'affiliation': []}, {'given': 'Eugenio', 'family': 'Giménez', 'sequence': 'additional', 'affiliation': []}, {'given': 'Pilar', 'family': 'Martínez-Barranco', 'sequence': 'additional', 'affiliation': []}, {'given': 'Juan José', 'family': 'Mateos', 'sequence': 'additional', 'affiliation': []}, {'given': 'Luis Felipe', 'family': 'Casado', 'sequence': 'additional', 'affiliation': []}, {'given': 'Joan', 'family': 'Bladé', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-3393-9570', 'authenticated-orcid': False, 'given': 'Juan José', 'family': 'Lahuerta', 'sequence': 'additional', 'affiliation': []}, {'given': 'Javier', 'family': 'de la Cruz', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-9183-4857', 'authenticated-orcid': False, 'given': 'Jesús', 'family': 'San-Miguel', 'sequence': 'additional', 'affiliation': []}], 'member': '297', 'published-online': {'date-parts': [[2020, 10, 19]]}, 'reference': [ { 'key': '372_CR1', 'unstructured': 'World Health Organization. Novel Coronavirus–China. World Health ' 'Organization. ' 'https://www.who.int/china/news/detail/09-01-2020-who-statement-regarding-cluster-of-pneumonia-cases-in-wuhan-china ' '(WHO, 2020).'}, { 'key': '372_CR2', 'doi-asserted-by': 'publisher', 'first-page': '1054', 'DOI': '10.1016/S0140-6736(20)30566-3', 'volume': '395', 'author': 'F Zhou', 'year': '2020', 'unstructured': 'Zhou, F. et al. Clinical course and risk factors for mortality of adult ' 'inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. ' 'Lancet 395, 1054–1062 (2020).', 'journal-title': 'Lancet'}, { 'key': '372_CR3', 'doi-asserted-by': 'publisher', 'first-page': '934', 'DOI': '10.1001/jamainternmed.2020.0994', 'volume': '180', 'author': 'C Wu', 'year': '2020', 'unstructured': 'Wu, C. et al. Risk factors associated with acute respiratory distress ' 'syndrome and death in patients with coronavirus disease 2019 pneumonia ' 'in Wuhan, China. JAMA Intern. Med. 180, 934–943 (2020).', 'journal-title': 'JAMA Intern. Med'}, { 'key': '372_CR4', 'doi-asserted-by': 'publisher', 'first-page': '1708', 'DOI': '10.1056/NEJMoa2002032', 'volume': '382', 'author': 'W-J Guan', 'year': '2020', 'unstructured': 'Guan, W.-J. et al. Clinical characteristics of coronavirus disease 2019 ' 'in China. N. Engl. J. Med. 382, 1708–1720 (2020).', 'journal-title': 'N. Engl. J. Med.'}, { 'key': '372_CR5', 'doi-asserted-by': 'publisher', 'first-page': '894', 'DOI': '10.1016/j.annonc.2020.03.296', 'volume': '31', 'author': 'L Zhang', 'year': '2020', 'unstructured': 'Zhang, L. et al. Clinical characteristics of COVID-19-infected cancer ' 'patients: a retrospective case study in three hospitals within Wuhan, ' 'China. Ann. Oncol. 31, 894–901 (2020).', 'journal-title': 'Ann. Oncol.'}, { 'key': '372_CR6', 'doi-asserted-by': 'publisher', 'first-page': '335', 'DOI': '10.1016/S1470-2045(20)30096-6', 'volume': '21', 'author': 'W Liang', 'year': '2020', 'unstructured': 'Liang, W. et al. Cancer patients in SARS-CoV-2 infection: a nationwide ' 'analysis in China. Lancet Oncol. 21, 335–337 (2020).', 'journal-title': 'Lancet Oncol.'}, { 'key': '372_CR7', 'doi-asserted-by': 'publisher', 'first-page': '1919', 'DOI': '10.1016/S0140-6736(20)31173-9', 'volume': '395', 'author': 'LYW Lee', 'year': '2020', 'unstructured': 'Lee, L. Y. W. et al. COVID-19 mortality in patients with cancer on ' 'chemotherapy or other anticancer treatments: a prospective cohort study. ' 'Lancet 395, 1919–1926 (2020).', 'journal-title': 'Lancet'}, { 'key': '372_CR8', 'doi-asserted-by': 'publisher', 'first-page': '107', 'DOI': '10.3324/haematol.2014.107714', 'volume': '100', 'author': 'C Blimark', 'year': '2015', 'unstructured': 'Blimark, C. et al. Multiple myeloma and infections: a population-based ' 'study on 9253 multiple myeloma patients. Haematologica 100, 107–113 ' '(2015).', 'journal-title': 'Haematologica'}, { 'key': '372_CR9', 'doi-asserted-by': 'publisher', 'first-page': '6145', 'DOI': '10.4049/jimmunol.0901596', 'volume': '183', 'author': 'M Basler', 'year': '2009', 'unstructured': 'Basler, M., Lauer, C., Beck, U. & Groettrup, M. The proteasome inhibitor ' 'bortezomib enhances the susceptibility to viral infection. J. Immunol. ' '183, 6145–6150 (2009).', 'journal-title': 'J. Immunol.'}, { 'key': '372_CR10', 'doi-asserted-by': 'publisher', 'first-page': '925', 'DOI': '10.1007/s00277-018-3284-y', 'volume': '97', 'author': 'M Chen', 'year': '2018', 'unstructured': 'Chen, M. et al. Immunomodulatory drugs and the risk of serious infection ' 'in multiple myeloma: systematic review and meta-analysis of randomized ' 'and observational studies. Ann. Hematol. 97, 925–944 (2018).', 'journal-title': 'Ann. Hematol.'}, { 'key': '372_CR11', 'doi-asserted-by': 'publisher', 'first-page': '4290', 'DOI': '10.1158/1078-0432.CCR-16-3192', 'volume': '23', 'author': 'X Feng', 'year': '2017', 'unstructured': 'Feng, X. et al. Targeting CD38 suppresses induction and function of T ' 'regulatory cells to mitigate immunosuppression in multiple myeloma. ' 'Clin. Cancer Res. 23, 4290–4300 (2017).', 'journal-title': 'Clin. Cancer Res.'}, { 'key': '372_CR12', 'doi-asserted-by': 'publisher', 'DOI': '10.1371/journal.pone.0211927', 'volume': '14', 'author': 'H Nahi', 'year': '2019', 'unstructured': 'Nahi, H. et al. Infectious complications and NK cell depletion following ' 'daratumumab treatment of multiple myeloma. PLoS ONE 14, e0211927 (2019).', 'journal-title': 'PLoS ONE'}, { 'key': '372_CR13', 'doi-asserted-by': 'publisher', 'first-page': '1307', 'DOI': '10.1182/bloodadvances.2020001907', 'volume': '4', 'author': 'X Zhang', 'year': '2020', 'unstructured': 'Zhang, X. et al. First case of COVID-19 in a patient with multiple ' 'myeloma successfully treated with tocilizumab. Blood Adv. 4, 1307–1310 ' '(2020).', 'journal-title': 'Blood Adv.'}, { 'key': '372_CR14', 'doi-asserted-by': 'publisher', 'unstructured': 'Cook, G. et al. Real-world assessment of the clinical impact of ' 'symptomatic infection with severe acute respiratory syndrome coronavirus ' '(COVID-19 disease) in patients with multiple myeloma receiving systemic ' 'anti-cancer therapy. Br. J. Haematol. https://doi.org/10.1111/bjh.16874 ' '(2020).', 'DOI': '10.1111/bjh.16874'}, { 'key': '372_CR15', 'doi-asserted-by': 'publisher', 'unstructured': 'Terpos, E. et al. Management of patients with multiple myeloma in the ' 'era of COVID-19 pandemic: a consensus paper from the European Myeloma ' 'Network (EMN). Leukemia. https://doi.org/10.1038/s41375-41020-40876-z ' '(2020).', 'DOI': '10.1038/s41375-41020-40876-z'}, { 'key': '372_CR16', 'doi-asserted-by': 'publisher', 'unstructured': 'Di Ciaccio, P. et al. Australian and New Zealand consensus statement on ' 'the management of lymphoma, chronic lymphocytic leukaemia and myeloma ' 'during the COVID-19 pandemic. Intern. Med. J. ' 'https://doi.org/10.1111/imj.14859 (2020).', 'DOI': '10.1111/imj.14859'}, { 'key': '372_CR17', 'doi-asserted-by': 'publisher', 'unstructured': 'Hungria, V. et al. Managing patients with multiple myeloma during the ' 'COVID-19 pandemic: recommendations from an expert panel—ABHH Monoclonal ' 'Gammopathies Committe. Hematol. Transfus Cell Ther. ' 'https://doi.org/10.1016/j.htct.2020.1005.1001 (2020).', 'DOI': '10.1016/j.htct.2020.1005.1001'}, { 'key': '372_CR18', 'doi-asserted-by': 'publisher', 'first-page': '764', 'DOI': '10.1016/j.jgo.2020.04.008', 'volume': '11', 'author': 'H Mian', 'year': '2020', 'unstructured': 'Mian, H. et al. Caring for older adults with multiple myeloma during the ' 'COVID-19 pandemic: perspective from the international forum for ' 'optimizing care of older adults with myeloma. J. Geriatr. Oncol. 11, ' '764–768 (2020).', 'journal-title': 'J. Geriatr. Oncol.'}, { 'key': '372_CR19', 'doi-asserted-by': 'publisher', 'unstructured': 'Al Saleh, A. S., Sher, T. & Gertz, M. A. Multiple myeloma in the time of ' 'COVID-19. Acta Haematol. https://doi.org/10.1159/000507690 (2020).', 'DOI': '10.1159/000507690'}, { 'key': '372_CR20', 'doi-asserted-by': 'publisher', 'first-page': '1470', 'DOI': '10.3324/haematol.2011.044933', 'volume': '96', 'author': 'E Barragan', 'year': '2011', 'unstructured': 'Barragan, E. et al. Prognostic value of FLT3 mutations in patients with ' 'acute promyelocytic leukemia treated with all-trans retinoic acid and ' 'anthracycline monochemotherapy. Haematologica 96, 1470–1477 (2011).', 'journal-title': 'Haematologica'}, { 'key': '372_CR21', 'doi-asserted-by': 'publisher', 'first-page': 'W1', 'DOI': '10.7326/M14-0698', 'volume': '162', 'author': 'KG Moons', 'year': '2015', 'unstructured': 'Moons, K. G. et al. Transparent reporting of a multivariable prediction ' 'model for individual prognosis or diagnosis (TRIPOD): explanation and ' 'elaboration. Ann. Intern. Med. 162, W1–W73 (2015).', 'journal-title': 'Ann. Intern. Med.'}, { 'key': '372_CR22', 'doi-asserted-by': 'publisher', 'first-page': '803', 'DOI': '10.1093/jnci/djy088', 'volume': '110', 'author': 'W Sauerbrei', 'year': '2018', 'unstructured': 'Sauerbrei, W., Taube, S. E., McShane, L. M., Cavenagh, M. M. & Altman, ' 'D. G. Reporting recommendations for tumor marker prognostic studies ' '(REMARK): an abridged explanation and elaboration. J. Natl Cancer Inst. ' '110, 803–811 (2018).', 'journal-title': 'J. Natl Cancer Inst.'}, { 'key': '372_CR23', 'doi-asserted-by': 'publisher', 'first-page': '280', 'DOI': '10.7326/0003-4819-158-4-201302190-00009', 'volume': '158', 'author': 'JA Hayden', 'year': '2013', 'unstructured': 'Hayden, J. A., van der Windt, D. A., Cartwright, J. L., Côté, P. & ' 'Bombardier, C. Assessing bias in studies of prognostic factors. Ann. ' 'Intern. Med. 158, 280–286 (2013).', 'journal-title': 'Ann. Intern. Med.'}, { 'key': '372_CR24', 'doi-asserted-by': 'publisher', 'first-page': '2012', 'DOI': '10.1056/NEJMoa2004500', 'volume': '382', 'author': 'PK Bhatraju', 'year': '2020', 'unstructured': 'Bhatraju, P. K. et al. Covid-19 in critically Ill patients in the ' 'Seattle region—case series. N. Engl. J. Med. 382, 2012–2022 (2020).', 'journal-title': 'N. Engl. J. Med.'}, { 'key': '372_CR25', 'doi-asserted-by': 'publisher', 'unstructured': 'Grasselli, G., Pesenti, A. & Cecconi, M. Critical care utilization for ' 'the COVID-19 outbreak in Lombardy, Italy: early experience and forecast ' 'during an emergency response. J. Am. Med. Assoc. ' 'https://doi.org/10.1001/jama.2020.4031 (2020).', 'DOI': '10.1001/jama.2020.4031'}, { 'key': '372_CR26', 'doi-asserted-by': 'publisher', 'unstructured': 'Martín-Moro, F. et al. Survival study of hospitalised patients with ' 'concurrent COVID-19 and haematological malignancies. Br. J. Haematol. ' 'https://doi.org/10.1111/bjh.16801 (2020).', 'DOI': '10.1111/bjh.16801'}, { 'key': '372_CR27', 'doi-asserted-by': 'publisher', 'unstructured': 'Fernández-Ruiz, M. et al. COVID-19 in solid organ transplant recipients: ' 'a single-center case series from Spain. Am. J. Transplant. ' 'https://doi.org/10.1111/ajt.15929 (2020).', 'DOI': '10.1111/ajt.15929'}, { 'key': '372_CR28', 'doi-asserted-by': 'publisher', 'first-page': '829', 'DOI': '10.1016/j.kint.2020.03.005', 'volume': '97', 'author': 'Y Cheng', 'year': '2020', 'unstructured': 'Cheng, Y. et al. Kidney disease is associated with in-hospital death of ' 'patients with COVID-19. Kidney Int. 97, 829–838 (2020).', 'journal-title': 'Kidney Int.'}], 'container-title': 'Blood Cancer Journal', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://www.nature.com/articles/s41408-020-00372-5.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://www.nature.com/articles/s41408-020-00372-5', 'content-type': 'text/html', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://www.nature.com/articles/s41408-020-00372-5.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2022, 12, 5]], 'date-time': '2022-12-05T14:35:57Z', 'timestamp': 1670250957000}, 'score': 1, 'resource': {'primary': {'URL': 'https://www.nature.com/articles/s41408-020-00372-5'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2020, 10, 19]]}, 'references-count': 28, 'journal-issue': {'issue': '10', 'published-online': {'date-parts': [[2020, 10]]}}, 'alternative-id': ['372'], 'URL': 'http://dx.doi.org/10.1038/s41408-020-00372-5', 'relation': { 'has-preprint': [ { 'id-type': 'doi', 'id': '10.1101/2020.06.29.20142455', 'asserted-by': 'object'}]}, 'ISSN': ['2044-5385'], 'subject': ['Oncology', 'Hematology'], 'container-title-short': 'Blood Cancer J.', 'published': {'date-parts': [[2020, 10, 19]]}, 'assertion': [ { 'value': '31 July 2020', 'order': 1, 'name': 'received', 'label': 'Received', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '6 August 2020', 'order': 2, 'name': 'revised', 'label': 'Revised', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '6 August 2020', 'order': 3, 'name': 'accepted', 'label': 'Accepted', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '19 October 2020', 'order': 4, 'name': 'first_online', 'label': 'First Online', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': 'M.-V.M. has received honoraria for lectures and participation in advisory ' 'boards from Janssen, Celgene-BMS, Amgen, Takeda, Abbvie, GSK, Adaptive, Roche, ' 'Seatle Genetics, Pfizer, and Regeneron. J.M.-L. has received honoraria for ' 'participation in advisory boards from Novartis, Roche, BMS, Adaptive, Incyte, ' 'Amgen, and Janssen-Cilag. J.S.-M. has received honoraria for lectures and ' 'advisory boards from Amgen, Bristol–Myers Squibb, Celgene, Janssen, Merck, ' 'Novartis, Takeda, Sanofi, and Roche. J.B. has received honoraria for lectures ' 'and advisory boards from Janssen, Celgene, Amgen, Takeda, and Oncopeptides. ' 'J.J.L. has received honoraria for lectures and advisory boards from Janssen, ' 'Celgene, Amgen, and Takeda. A.L. has received honoraria for advisory boards ' 'from Celgene, Amgen, and Janssen. P.M.-B. has received honoraria for advisory ' 'boards from Amgen. A.S. has received honoraria for advisory boards from Takeda, ' 'BMS, MSD, Sanofi, Roche, Novartis, Janssen, and Sandoz, and for a consultancy ' 'from Takeda, BMS, Novartis, Celgene, Janssen, Gilead, and Sanofi, and has ' 'received honoraria as a member of a Speakers Bureau for Takeda. F.E. has ' 'received honoraria for advisory boards from Celgene and Amgen. E.P.P. has ' 'received honoraria for advisory boards from Amgen and for lectures from ' 'BMS/Celgene and Janssen. C.F.d.L. has received honoraria for advisory boards ' 'from BMS/Celgene, Amgen, Takeda, and Janssen. L.F.C. reports honoraria for ' 'lectures from and membership on advisory boards with Celgene, Janssen, Roche, ' 'Novartis, Bristol–Myers Squibb, Amgen, Takeda, Pfizer, Incyte, and AbbVie. The ' 'remaining authors declare that they have no conflict of interest.', 'order': 1, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Conflict of interest'}}], 'article-number': '103'}